Bassiri M, Mårdh P A, Domeika M
Institute of Clinical Bacteriology, Uppsala University, Sweden.
J Clin Microbiol. 1997 Oct;35(10):2556-60. doi: 10.1128/jcm.35.10.2556-2560.1997.
A new PCR kit (AMPLICOR CT/NG; Roche Diagnostic Systems, Inc., Branchburg, N.J.) was used as a screening tool for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in first-void urine (FVU) specimens from 3,340 asymptomatic women attending European health care units for contraceptive advice or pregnancy termination. All samples were kept frozen (-20 degrees C) prior to testing. Chlamydia-positive samples were retested once by the plasmid-based PCR kit and also by a major outer membrane protein (MOMP) primer-based PCR. Discrepancies were resolved by using the direct immunofluorescence test (DIF) with the centrifuged sediment of the FVU specimens. Samples positive for N. gonorrhoeae were retested by chromosomal primer-based PCR and verified by a 16S RNA PCR. Of the samples tested, 1.8% were considered inhibitory by using the internal amplification control. Of 81 samples positive for C. trachomatis, 74 samples were positive by both plasmid- and MOMP-based PCRs, 6 samples were positive by plasmid-based PCR and DIF, and one sample was positive by both MOMP-based PCR and DIF. Nine samples (0.3%) were positive for N. gonorrhoeae by the chromosomal primer-based PCR; however, none of the results could be confirmed. The test offers the unique ability to identify inhibition of amplification with the optional internal control.
一种新的聚合酶链反应试剂盒（AMPLICOR CT/NG；罗氏诊断系统公司，新泽西州布兰奇堡）被用作筛选工具，用于检测3340名到欧洲医疗保健机构寻求避孕建议或终止妊娠的无症状女性的首次晨尿（FVU）样本中的沙眼衣原体和淋病奈瑟菌。所有样本在检测前均保存在-20℃的冷冻状态。沙眼衣原体阳性样本先用基于质粒的聚合酶链反应试剂盒重新检测一次，也用基于主要外膜蛋白（MOMP）引物的聚合酶链反应进行检测。通过对FVU样本的离心沉淀物进行直接免疫荧光试验（DIF）来解决差异。淋病奈瑟菌阳性样本用基于染色体引物的聚合酶链反应重新检测，并通过16S RNA聚合酶链反应进行验证。在检测的样本中，使用内部扩增对照时，1.8%的样本被认为具有抑制作用。在81份沙眼衣原体阳性样本中，74份样本通过基于质粒和MOMP的聚合酶链反应均呈阳性，6份样本通过基于质粒的聚合酶链反应和DIF呈阳性，1份样本通过基于MOMP的聚合酶链反应和DIF均呈阳性。9份样本（0.3%）通过基于染色体引物的聚合酶链反应检测淋病奈瑟菌呈阳性；然而，没有一个结果能够得到证实。该检测方法具有通过可选的内部对照识别扩增抑制的独特能力。
